Squamous Cell Carcinoma of the Oral Cavity Clinical Trial
Official title:
Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study (SNOW)
This is a window of opportunity study for patients with resectable squamous cell carcinoma of the oral cavity who are considered suitable for curative-intent surgical resection, with pre-operative drugs, Sitravatinib and Nivolumab.
This is a single center, open-label, non-randomized, pre-operative window of opportunity study for patients with resectable squamous cell carcinoma of the oral cavity who are considered suitable for curative-intent surgical resection, with pre-operative Sitravatinib and Nivolumab. A total of 12 patients who are evaluable for correlative studies, are planned for enrollment. This study will involve treatment with Sitravatinib and Nivolumab, tests and procedures done for safety and the collection of blood samples for biomarker research. Tissue samples (fresh biopsy or archival tissue) will also be collected for biomarker research and evaluation. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05540899 -
Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer
|
Phase 1 | |
| Completed |
NCT01108042 -
TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06380686 -
Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
|
||
| Active, not recruiting |
NCT03721757 -
CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer
|
Phase 2 | |
| Completed |
NCT02873819 -
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
|
Phase 2 | |
| Active, not recruiting |
NCT04387682 -
Myeloid-derived Suppressor Cells (MDSCs) in OSCC Patients
|
N/A | |
| Completed |
NCT01321892 -
Ex Vivo Multimodal Imaging of Upper Aerodigestive Epithelium
|
N/A | |
| Completed |
NCT01636544 -
Infectious Aetiology of Potentially Malignant Disorders and Squamous Cell Carcinomas of the Oral Cavity
|
N/A | |
| Not yet recruiting |
NCT05608369 -
Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC
|
Phase 2 | |
| Withdrawn |
NCT04831450 -
Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)
|
Phase 2 | |
| Recruiting |
NCT04191460 -
Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer
|
Phase 2 | |
| Recruiting |
NCT06030440 -
De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
|
Phase 2/Phase 3 | |
| Terminated |
NCT01077869 -
A Feasibility Study on the Use of F-18-FDG-PET and Optical Imaging in Evaluation of Radiation-induced Oral Mucositis
|
Phase 1 | |
| Completed |
NCT02609386 -
IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
|
Phase 2 | |
| Not yet recruiting |
NCT05452408 -
Antitumor-B KAC PK Study
|
Phase 1 | |
| Not yet recruiting |
NCT03364166 -
Recurrence in Buccinator Muscle Excision With the Skin Versus Without the Skin in Buccal Squamous Cell Carcinoma
|
N/A | |
| Terminated |
NCT02331875 -
Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity
|
Phase 1/Phase 2 | |
| Completed |
NCT01265849 -
Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity
|
Phase 3 | |
| Active, not recruiting |
NCT03370276 -
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03459729 -
Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer
|
Early Phase 1 |